Sage Therapeutics to Present at Piper Sandler Healthcare Conference Dec 4 - StockTitan
Embattled Sage Dealt Deeper Blow With Huntington’s Failure - BioSpace
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Q1 EPS Estimate for Sage Therapeutics Increased by Analyst - MarketBeat
Q1 Earnings Forecast for Sage Therapeutics Issued By Wedbush - MarketBeat
Sage Therapeutics to end development of key therapy after a third trial failure - MSN
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
Sage Therapeutics, Inc. Sued for Securities Law Violations - Con - GuruFocus.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $12.83 Average Price Target from Analysts - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of "Hold" by Analysts - MarketBeat

Pages